Co-Diagnostics Expands Commercial Presence Across South Asia, Targeting $13 Billion Market Co-Diagnostics announces a significant expansion into four South Asian countries, enhancing its market potential to $13 billion while focusing on point-of-care solutions.

Co-Diagnostics Expands Commercial Presence Across South Asia, Targeting $13 Billion Market #United_States #Salt_Lake_City #Co-Diagnostics #PCR_Technology #South_Asia

Co-Diagnostics Secures Japanese Patent for Revolutionary PCR Technology Advancements Co-Diagnostics has been awarded a significant Japanese patent for its innovative PCR platform technology, enhancing global diagnostics efforts.

Co-Diagnostics Secures Japanese Patent for Revolutionary PCR Technology Advancements #Japan #Salt_Lake_City #Co-Diagnostics #PCR_Technology #Japanese_Patent

Co-Diagnostics Unveils Innovative Sample Prep Instrument for TB Testing Accessibility Co-Diagnostics has developed a new sample prep instrument aimed at simplifying TB testing in resource-limited settings. This advancement could significantly impact healthcare accessibility.

Co-Diagnostics Unveils Innovative Sample Prep Instrument for TB Testing Accessibility #United_States #Salt_Lake_City #Co-Diagnostics #PCR_Technology #TB_Testing

Co-Diagnostics, Inc. to Showcase Innovative PCR Technology at WHX Kuala Lumpur 2025 Co-Diagnostics, Inc. is set to exhibit at WHX Kuala Lumpur from July 16-18, 2025, showcasing their advancements in molecular diagnostics and PCR technologies.

Co-Diagnostics, Inc. to Showcase Innovative PCR Technology at WHX Kuala Lumpur 2025 #United_States #Salt_Lake_City #Co-Diagnostics #PCR_Technology #WHX_Kuala_Lumpur

Seegene Unveils STAgora™: A Revolutionary Platform for Infectious Disease Analysis Seegene introduces STAgora™, a cutting-edge platform designed to revolutionize infectious disease analysis through real-time data integration.

Seegene Unveils STAgora™: A Revolutionary Platform for Infectious Disease Analysis #South_Korea #Seoul #PCR_Technology #Seegene #STAgora™

Seegene Unveils STAgora™: A Game-Changing Platform for Infectious Disease Analysis Seegene has launched STAgora™, a cutting-edge platform designed for real-time analysis of infectious diseases, enhancing pandemic preparedness and clinical decision-making.

Seegene Unveils STAgora™: A Game-Changing Platform for Infectious Disease Analysis #South_Korea #Seoul #PCR_Technology #Seegene #STAgora

Seegene Unveils Groundbreaking CURECA™: A New Era in Fully Automated PCR Technology Seegene Inc. has announced the launch of CURECA™, an innovative fully automated PCR system poised to revolutionize laboratory testing. Discover the future of molecular diagnostics.

Seegene Unveils Groundbreaking CURECA™: A New Era in Fully Automated PCR Technology #USA #Seoul #PCR_Technology #Seegene #CURECA

Seegene Introduces CURECA™, an Innovative Automated PCR Solution with Customizable Pre-Treatment Seegene Inc. has unveiled CURECA™, an advanced automated PCR system designed to enhance laboratory workflows and improve diagnostic efficiency.

Seegene Introduces CURECA™, an Innovative Automated PCR Solution with Customizable Pre-Treatment #South_Korea #Seoul #PCR_Technology #Seegene #CURECA

Molecular Infectious Disease Testing Market Poised for Significant Growth by 2029 The Molecular Infectious Disease Testing market is projected to reach USD 17.78 billion by 2029, demonstrating a CAGR of 13.7%. Key factors driving its growth include rising infectious diseases and advanced diagnostics.

Molecular Infectious Disease Testing Market Poised for Significant Growth by 2029 #USA #Delray_Beach #PCR_Technology #Infectious_Diseases #Molecular_Testing

Projected Growth in Minimal Residual Disease Market: USD 2.55 Billion by 2029 The Minimal Residual Disease market is anticipated to reach USD 2.55 billion by 2029, showing a robust growth rate driven by cancer incidence and technological advancements.

Projected Growth in Minimal Residual Disease Market: USD 2.55 Billion by 2029 #None #Minimal_Residual_Disease #IGRA_Testing #PCR_Technology